Wellington Management Group LLP Buys 906,114 Shares of Moderna, Inc. (NASDAQ:MRNA)

Wellington Management Group LLP lifted its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 21.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,224,685 shares of the company's stock after buying an additional 906,114 shares during the period. Wellington Management Group LLP owned approximately 1.36% of Moderna worth $349,166,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the company. State Street Corp increased its holdings in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock valued at $1,125,899,000 after buying an additional 1,823,276 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Moderna by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company's stock valued at $260,023,000 after acquiring an additional 19,819 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Moderna by 6.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company's stock worth $205,431,000 after purchasing an additional 178,939 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Moderna by 4.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,132,777 shares of the company's stock worth $142,533,000 after purchasing an additional 83,082 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company's stock worth $107,885,000 after purchasing an additional 167,596 shares during the period. Institutional investors own 75.33% of the company's stock.

Moderna Trading Up 3.5 %

Shares of Moderna stock traded up $1.50 during trading on Friday, hitting $44.44. The stock had a trading volume of 8,735,641 shares, compared to its average volume of 10,344,880. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm's fifty day simple moving average is $50.27 and its 200-day simple moving average is $87.86. The stock has a market cap of $17.10 billion, a PE ratio of -7.64 and a beta of 1.58.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.39) earnings per share. As a group, sell-side analysts expect that Moderna, Inc. will post -9.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on MRNA shares. TD Cowen lowered their price objective on Moderna from $70.00 to $60.00 and set a "hold" rating on the stock in a research report on Friday, September 13th. Piper Sandler reiterated an "overweight" rating and issued a $69.00 price target (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Hsbc Global Res raised Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Oppenheimer downgraded shares of Moderna from an "outperform" rating to a "market perform" rating in a report on Friday, September 13th. Finally, Berenberg Bank started coverage on shares of Moderna in a report on Tuesday, November 19th. They set a "hold" rating and a $42.00 price objective for the company. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Moderna presently has an average rating of "Hold" and an average price target of $83.33.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company's stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 715 shares of the business's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,850 shares of company stock worth $134,560. 15.70% of the stock is currently owned by insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.